TATA HEALTH (01255) receives additional resumption guidance from the Hong Kong Stock Exchange.
TATA Health (01255) announced that on September 12, 2025, the company received a letter from the Hong Kong Stock Exchange...
TATA HEALTH (01255) announced that on September 12, 2025, the company received a letter from the Stock Exchange listing additional guidance for the resumption of trading. The letter specified that the company must conduct an independent internal control review and demonstrate that it has established sufficient internal controls and procedures to meet its responsibilities under the listing rules.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
